Strong commercial performance of IBSRELA continues, ending FY 2023 with $80.1 million in net product sales revenue; 2024 net product sales revenue currently expected to be between $140.0 to $150.0
HbA1c is less reliable in patients with CKD. A study found that glycated albumin associates with important long-term clinical outcomes in a non-dialysis CKD population.
HbA1c is less reliable in patients with CKD. A study found that glycated albumin associates with important long-term clinical outcomes in a non-dialysis CKD population.
The 72-week open-label extension of the phase 2b ORIGIN trial reveals atacicept's potential as a disease-modifying treatment for IgA nephropathy, showing eGFR stabilization and improvements in key indicators
Denmark: A recent study revealed that elevated albumin in the urine may be linked with sub-clinical coronary artery pathology, including coronary artery microcalcifications in individuals with type 2.